A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2025

Conditions

Indolent B-cell Lymphoma

Interventions

DRUG

Linperlisib

Linperlisib is a small molecule inhibitor of phosphoinositol 3-kinase-δ (PI3K-δ)

All Listed Sponsors

lead

Shanghai YingLi Pharmaceutical Co. Ltd.

INDUSTRY

NCT06343935 - A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma | Biotech Hunter | Biotech Hunter